Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer

Hidetoshi Hayashi, Isamu Okamoto, Shinya Ueda, Kaoru Tanaka, Kunio Okamoto, Hisato Kawakami, Shinichi Nishina, Masayuki Takeda, Yasuhito Fujisaka, Taroh Satoh, Kyoichi Terao, Yasumasa Nishimura, Katsumi Doi, Kazuhiko Nakagawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Aim: We performed a pharmacokinetic phase I trial of the combination of S-1 granules and nedaplatin for head and neck squamous cell carcinoma (HNSCC). Patients and Methods: Patients were treated with both nedaplatin on day 1 at a dose starting at 80 mg/m2 (level 1) escalating up to 90 mg/m2 (level 2), and S-1 granules at a daily dose of 80 mg/m2 on days 1 to 14 every three weeks. The primary end-point was determination of the recommended dose. Results: Twenty patients were enrolled. Dose-limiting toxicities occurred in one out of six patients at dose level 1 (neutropenia) and in all three patients at level 2 (neutropenia and thrombocytopenia). The recommended dose was determined as level 1. Pharmacokinetic parameters of S-1 granule did not differ from the capsula formulation. The response rate was 42.1%. Conclusion: This combination was well-tolerated and manifested a promising activity against HNSCC.

Original languageEnglish
Pages (from-to)5699-5706
Number of pages8
JournalAnticancer research
Issue number12
Publication statusPublished - Dec 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer'. Together they form a unique fingerprint.

Cite this